Diabetes technology for pregnant women with hyperglycemia in pregnancy: An opportunity to address global inequity

Aris T. Papageorghiou, Hema Divakar, Fionnuala M McAuliffe, Moshe HodInternational Journal of Gynecology & Obstetrics 2026 · DOI

Abstract

The recently published joint clinical practice guideline from the Endocrine Society and the European Society of Endocrinology on pre-existing diabetes and pregnancy is a thorough synthesis of available evidence and includes technology-based strategies.1 The recommendations span preconception to postpartum care and aim to improve pregnancy outcomes in individuals with type 1 and type 2 diabetes. Diabetes in pregnancy commonly co-exists with chronic hypertension and maternal obesity, which potentiates placental dysfunction and cardiometabolic risk, increasing adverse maternal and perinatal outcomes; this highlights the requirement for intensified surveillance and integrated management of these comorbidities to assure quality care. While the guideline aspires to be relevant for all women with diabetes contemplating or experiencing pregnancy, it makes minimal reference to the overwhelming burden of hyperglycemia in pregnancy (HIP) in low- and middle-income countries (LMICs). The absence of implementation strategies adapted for such contexts is a structural omission with important consequences. In this commentary, we address both the broader HIP burden and specific considerations for women with pre-existing diabetes, and we indicate where recommendations diverge. Global applicability and equity dimensions have been insufficiently addressed in several previous guidelines. Hyperglycemia is among the most common medical conditions in pregnancy. The International Diabetes Federation estimates that one in six live births (16.8%) occurs in women with some form of HIP. Of these, approximately 16% are due to diabetes in pregnancy (either pre-existing or first identified during the index pregnancy), with the remainder (84%) due to gestational diabetes. The smaller but higher-risk subgroup with diabetes often requires more intensive, technology-enabled management; the larger group with gestational diabetes can frequently be managed with simpler, affordable approaches depending on context. Crucially, all women, regardless of where they live, should receive the level and quality of care they need. Adaptation to local resources is a pathway to equity, not a lowering of standards. Over 90% of the world's 135 million annual births occur in LMICs, yet most pregnancy guidelines, including those for complications such as diabetes in pregnancy, are developed in high-income countries without due consideration of LMIC realities. This creates a critical gap: women in resource-limited settings are expected to follow protocols designed for well-resourced environments, often relying on costly technologies that are impractical or unaffordable. As a result, implementation falters and impact remains limited.2, 3 Pragmatic, context-specific strategies can drive meaningful improvements when widely adopted. The International Federation of Gynecology and Obstetrics (FIGO), with 142 member societies, is uniquely well placed to close this gap by embedding resource-appropriate approaches into global standards, ensuring that most the world's pregnant women benefit from guidance reflecting their needs and realities. FIGO's four-tier resource classification acknowledges within-country disparities; many affluent nations have under-resourced areas, while LMICs may contain pockets of high-quality care.3-7 Pregnant women living in LMICs are at the epicenter of the global HIP burden, where adverse maternal and perinatal outcomes are most severe and least preventable. Yet, the recent guideline omits LMIC-specific considerations and strategies for constrained health systems. The FIGO 2015 global guideline on HIP specifically addresses screening, diagnosis, and management in LMICs, and its guidance on prevention of type 2 diabetes after gestational diabetes has been adopted by governments such as India's, enabling wide coverage for early detection and management.3-5 The lack of cross-referencing between these and the new guideline is regrettable, especially given FIGO's inclusion as a participating organization. Such disconnect undermines coherence and risks fragmenting international maternal health policy.3-7 Here the shift from general HIP to pre-existing diabetes is particularly marked. The GRADE Evidence-to-Decision framework used in the guideline includes acceptability, feasibility, resource use, and impact on health equity. However, these considerations are only lightly reflected in the final recommendations. For example, the promotion of continuous glucose monitoring (CGM), hybrid closed-loop systems, and intensive preconception care is presented without stratification for contexts where insulin or even basic antenatal care are not universally available. These technologies are primarily relevant to women with pre-existing diabetes, yet their feasibility and cost-effectiveness in LMICs are not discussed. These advanced technologies, while transformative for women with pre-existing diabetes in well-resourced settings, must ultimately be accessible to all women. In the interim, context-adapted strategies are essential to bridge gaps in availability without compromising quality, for example, prioritizing reliable insulin supply, structured education, simplified monitoring protocols, and integrated antenatal pathways as foundational steps that enable later scale-up of technology.8 Preconception care, as the guideline rightly notes, depends on robust health systems, early engagement, and continuity of care—elements often fragmented in underserved regions. The potential of simplified, task-shared antenatal models, whereby primary or community health workers deliver components of diabetes management with clear escalation pathways, is absent from the recommendations, despite evidence of improved access for both gestational and pre-existing diabetes. Phased technology introduction (e.g., intermittent CGM loan programs—short-term use of professional or intermittent devices when continuous personal CGM is not feasible—and community-based data-upload hubs) can extend benefits while safeguarding equity.8 The guideline offers valuable insights for well-resourced settings but should be complemented by a dedicated global consensus supplement, led by FIGO and partners, focused on HIP care pathways in LMICs. Informal discussions within FIGO's Committee on Women's Health and Technology and with international partners indicate broad support for an updated, consensus framework explicitly tailored to resource-limited settings. FIGO and partners are well placed to coordinate development of such guidance. A focused supplement would align with existing evidence and explicitly address equity gaps in current global recommendations. Operationalizing equity means embedding it within guideline design, not treating it as an afterthought. Without this, the vast majority of women affected by HIP in LMICs risk continued exclusion from evidence-based, actionable care. ATP and MH conceived the commentary, synthesized the guideline and equity arguments and drafted the initial manuscript. HD contributed substantive content on LMIC implementation constraints and FIGO-relevant framing and critically revised the manuscript. FMM contributed specialist input on diabetes-in-pregnancy clinical management and technology-enabled surveillance pathways and critically revised the manuscript for clinical accuracy and balance. MH additionally contributed specialist input on FIGO guidance, global policy implications, and the clinical–public health interface and critically revised the manuscript. All authors approved the final version for submission and accept accountability for all aspects of the work. The authors declare no conflicts of interest. Data sharing is not applicable to this article as no new data were created or analyzed in this study.
BibTeX
@article{papageorghiou2026diabetes,
  author = {Aris T. Papageorghiou and Hema Divakar and Fionnuala M McAuliffe and Moshe Hod},
  title = {{Diabetes technology for pregnant women with hyperglycemia in pregnancy: An opportunity to address global inequity}},
  journal = {International Journal of Gynecology \& Obstetrics},
  year = {2026},
  doi = {10.1002/ijgo.70794},
}

Loading related content...

Figure